GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Current Deferred Taxes Liabilities

Kyverna Therapeutics (Kyverna Therapeutics) Current Deferred Taxes Liabilities : $0.00 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Kyverna Therapeutics's current deferred tax liabilities for the quarter that ended in Mar. 2024 was $0.00 Mil.

Kyverna Therapeutics Current Deferred Taxes Liabilities Historical Data

The historical data trend for Kyverna Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Current Deferred Taxes Liabilities Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Current Deferred Taxes Liabilities
- - -

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Current Deferred Taxes Liabilities Get a 7-Day Free Trial - - - - -

Kyverna Therapeutics Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines